Mal-PEG4-Glu(TFP ester)-NH-m-PEG24

Cat. No.: HY-140998: Ficha de datos Instrucciones de manejo
FAQs
Technical Support

Mal-PEG4-Glu(TFP ester)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Para uso exclusivo en investigación. No vendemos a pacientes.

Mal-PEG4-Glu(TFP ester)-NH-m-PEG24 Estructura química

No. CAS : 2408741-87-5

Tamaño		Stock
MOQ		Minimum order quantity
50 mg		Obtener un presupuesto
100 mg		Obtener un presupuesto
250 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Ver todos los productos específicos de isoformas PROTAC Linkers:

Ver todas las isoformas

PEG Linkers Alkyl-Chain Linkers Alkyl/ether Linkers

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Mal-PEG4-Glu(TFP ester)-NH-m-PEG24 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs^[1].

IC₅₀ & Target

PEGs

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peso molecular

1763.90

Fòrmula

C₇₈H₁₃₄F₄N₄O₃₅

No. CAS

2408741-87-5

SMILES

O=C(C(NC(CCOCCOCCOCCOCCNC(CCN1C(C=CC1=O)=O)=O)=O)CCC(OC2=C(F)C(F)=CC(F)=C2F)=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Instrucciones de manejo (2659 KB)

Referencias

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 [Content Brief]